HORIZON-Lung: what clinicians are saying
trastuzumab rezetecan (SHR-A1811) in advanced HER2-mutant non-small cell lung cancer · NCT04818333 ↗ · Phase 1/Phase 2 · Jiangsu HengRui Medicine Co., Ltd.
The clinicians cited read HORIZON-Lung favorably for its tumor responses, while a physician remains undecided about its place among HER2-directed ADCs. Differing interstitial lung disease summaries are not necessarily equivalent safety measures, and the emphasis on low discontinuation does not establish negligible pulmonary risk. The separate first-line comparison with chemo-immunotherapy is mentioned without comparative outcomes, not as evidence for moving treatment earlier.
Created with AI · how we check it
- edition 1
- commentary checked Nov 21, 2026
- 50 verified statements
This edition $750, with MCP access for your AI agent. Get this report
3 findings, and what sits behind each
01. Another HER2 ADC: a clinician questions its need and place in treatment
1 of the report's 3 cited clinicians · 7 statements from 2 speakers in 4 sources, 1 of them a podcast or video · 12 passages
Limitations recorded: 2.
Draws on: The comparison, Primary endpoint: Phase2:ObjectiveResponse Rate (ORR), Secondary endpoints, Population and setting.
02. HORIZON-Lung: what speakers highlight in response rates after prior therapy
3 of the report's 3 cited clinicians · 16 statements from 4 speakers in 10 sources, 1 of them a podcast or video · 15 passages
Limitations recorded: 4.
Draws on: Population and setting, Primary endpoint: Phase2:ObjectiveResponse Rate (ORR), Secondary endpoints, Design and conduct, The comparison, Safety and tolerability.
03. Responses: what speakers say
2 of the report's 3 cited clinicians · 9 statements from 3 speakers in 10 sources · 11 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Primary endpoint: Phase2:ObjectiveResponse Rate (ORR), Population and setting, Secondary endpoints, Design and conduct.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 3
1 of the report's 3 cited clinicians
Another HER2 ADC: a clinician questions its need and place in treatment
7 statements from 2 speakers in 4 sources, 1 of them a podcast or video
1 of the 2 named speakers in this finding holds this view, a confirmed clinician
- 7
- statements
- 12
- passages
- 4
- sources
- 2
- speakers
What the statements areViews 1Questions and uncertainty 1Clinical experience 0Comparisons 2Restated results and context 3Statement-to-passage links (a passage can back several statements)Supporting a statement 13Giving context 1Recorded with the findingLimitations: 2
1 post or article · 1 podcast or video · 2 publications
Draws on: The comparison, Primary endpoint: Phase2:ObjectiveResponse Rate (ORR), Secondary endpoints, Population and setting.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
Abbreviations (12)
ADC, antibody–drug conjugate; AE, adverse event; CNS, central nervous system; HCP, healthcare professional; HER2, human epidermal growth factor receptor 2; ILD, interstitial lung disease; MCP, Model Context Protocol, how AI agents read the report; MTD, maximum tolerated dose; NPI, National Provider Identifier, the US registry number for clinicians; NSCLC, non-small cell lung cancer; ORR, objective response rate; RP2D, recommended phase 2 dose.
The full HORIZON-Lung report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians still need to see from HORIZON-Lung to define the niche for trastuzumab rezetecan (SHR-A1811) among HER2-directed ADCs in advanced HER2-mutant NSCLC after platinum-based chemotherapy and anti-PD-(L)1 treatment?
From finding F1 (7 statements from 2 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 37commentary sources screened
- 15sources cited by verified statements
- 5named in screened sources
- 5speakers cited in the report
- 4cited speakers with a verified identity
3 cited clinicians, speakers with a confirmed clinical role, of them 3 physicians. By role and specialty:
- 2 physician, Medical oncology
- 1 physician, specialty not confirmed
Also in the sources: 3 organizational or shared accounts, not counted as people.
- 50verified statements, each linked to its source
- 9of them from speakers with a confirmed clinical role
- 3findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 4 sections | Paid |
| Verified statements with short source quotes and links | 50 | Paid |
| Who said each statement: the cited speakers | 5 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 4 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 15 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
10 discussed · 4 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811no commentary found | 0 | 0 |
| Primary endpoint: Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811no commentary found | 0 | 0 |
| Primary endpoint: Phase1: Maximum tolerated dose (MTD)no commentary found | 0 | 0 |
| Primary endpoint: Phase 1: Recommended Phase 2 dose (RP2D)no commentary found | 0 | 0 |
| Primary endpoint: Phase2:ObjectiveResponse Rate (ORR) | 6 | 9 |
| Secondary endpoints | 5 | 8 |
| Population and setting | 8 | 11 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 2 | 2 |
| Safety and tolerability | 4 | 7 |
| Design and conduct | 2 | 2 |
| Clinical niche and differentiation from other HER2-directed options | 3 | 3 |
| ADC classification and design framing | 2 | 2 |
| Related AACR25 drug commentary after chemo-immunotherapy | 1 | 1 |
| First-line phase III development beyond the reported population | 1 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
50 verified statements from 15 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 3 statements · 6% | ||||
| Podcasts | 3 | 1 | 1 | |
| Posts · 16 statements · 32% | ||||
| X threads | 16 | 12 | 35 | |
| LinkedIn posts | 0 | 0 | 1 | |
| Primary sources · 31 statements · 62%cited for context, not screened | ||||
| Publications | 31 | 2 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 21 / quarter
- Screened window
- Feb 26, 2025 → Sep 11, 2026
- Cited window
- Feb 26, 2025 → May 7, 2025
- Retrieved
- Nov 21, 2026
The trial
from ClinicalTrials.gov- Title
- Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1811 for Injection in Subjects With Advanced Non-small Cell Lung Cancer Who Have HER2 Expression , Amplification, or Mutation
- Registry
- NCT04818333
- Study IDs
- SHR-A1811-I-103
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Design
- Phase 1/Phase 2 · Interventional, single group
- Status
- Unknown
- Enrollment
- 157 actual
- Registered
- 2021-03-26
- Start
- 2021-04-23 actual
- Primary completion
- 2025-06 estimated
- Primary endpoints
- Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811
- Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811
- Phase1: Maximum tolerated dose (MTD)
- Phase 1: Recommended Phase 2 dose (RP2D)
- Phase2:ObjectiveResponse Rate (ORR)
- Interventions
- 1 registered
More on: Non-small cell lung cancer
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 1 clinician view in the sources used in this report is not yet captured as evidence in this edition.
- 47 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 34 sources about other trials or topics are not included.
- Public podcast and X discussion cannot establish how common these opinions are or whether they have changed routine treatment choices.
Show all 11 known gaps +Fewer −
- Repeated posts from one unnamed account and reposts do not add independent clinician opinions. Organizational summaries and relayed wording are not equivalent to individually expressed HCP assessments.
- Clinical roles are not established for several account authors. Source-described credentials or roles should not be treated as independently confirmed.
- Differing ILD percentages and response-duration descriptions are preserved as attributed. The sources do not fully reconcile their definitions or reporting time points.
- The reported clinical populations discussed here were HER2-mutant. The views do not establish benefit in HER2-overexpressing or amplified-only NSCLC, after another HER2 ADC, or in untreated or active CNS disease.
- The first-line phase III update concerns a separate study. The relevant post does not name HORIZON-Lung, and no first-line comparative outcomes are provided in that statement.
- No standalone trial protocol or exact regulatory label for SHR-A1811 was available in the sources reviewed, limiting fuller assessment of protocol details and regulatory positioning.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 21, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. HORIZON-Lung (NCT04818333): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/horizon-lung-nct04818333
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "HORIZON-Lung" (NCT04818333), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "horizon-lung-nct04818333". If you cannot make requests, read https://www.erudio.com/reports/horizon-lung-nct04818333.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT04818333", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT04818333 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/horizon-lung-nct04818333.json
curl https://www.erudio.com/reports/horizon-lung-nct04818333.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "horizon-lung-nct04818333" })release 6c7023d034c1451c2376fc272f3ae2892a737ad8d16de31265ef15d76e60e493
Questions
How much does the HORIZON-Lung report cost?
One edition costs $750 (Focused · 50 verified statements · 9 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the HORIZON-Lung report cover?
50 statements from 15 sources (1 podcast, 12 posts, 2 papers), 9 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the HORIZON-Lung report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "horizon-lung-nct04818333" }) previews it and create_order({ "report": "horizon-lung-nct04818333", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the HORIZON-Lung report?
Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.